# OnCo record nct03711032 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03711032/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03711032", "NCT03711032" ;
  schema:name "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)"@en ;
  schema:alternateName "KEYNOTE-676"@en ;
  schema:description "A phase 3 trial of Pembrolizumab in bladder & urothelial cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03711032/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03711032> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "3" ;
  schema:startDate "2018-12-24" ;
  onco:cancers <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/non-muscle-invasive-bladder-cancer/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/> ;
  onco:companies <https://onco.cc/companies/merck/> .